Is Johnson & Johnson a Buy for Summer 2021?

49
24
Favorite

Is Johnson & Johnson a Buy for Summer 2021?

Motley Fool2021-05-25

Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（24）

Ajinomoto
·2021-05-25
Denfensive stock .
Reply
1
Report
Fold Replies
- Niki2307:
  ???
  2021-05-25
  Reply
  Report
JamieB
·2021-05-25
Not bad
Reply
Like
Report
AlvintheTige
·2021-05-25
Not sure but u need to see the company fundamentals!!
Reply
4
Report
Fold Replies
- halforc:
  agree
  2021-05-25
  Reply
  Report
- theunmouse:
  True
  2021-05-25
  Reply
  Report
Uday
·2021-05-25
Good stock
Reply
4
Report
Fold Replies
- Al385:
  True
  2021-05-26
  Reply
  Report
- Raae:
  ??
  2021-05-25
  Reply
  Report
Shadowrider
·2021-05-25
Buy?
Reply
2
Report
Tatsuya
·2021-05-25
J&J vaccine
Reply
2
Report
Fold Replies
- Raae:
  ??
  2021-05-25
  Reply
  Report
iImba
·2021-05-25
No thanks
Reply
1
Report
Fold Replies
- Shadowrider:
  Good
  2021-05-25
  Reply
  Report
Egging
·2021-05-25
LIKE N COMMENT
Reply
6
Report
Fold Replies
- Pplymm:
  Comment for comment pls!
  2021-05-25
  Reply
  Report
- Tatsuya:
  ok
  2021-05-25
  Reply
  Report
- TatsuyaReplying toDsd:
  ...
  2021-05-25
  Reply
  Report
View more 2 comments
JonLucky
·2021-05-25
Perceptions always loom larger than reality.
Reply
4
Report
Fold Replies
- Kikiooi:
  AGree.
  2021-05-25
  Reply
  Report
Qarah
·2021-05-25
Like and comment pls
Reply
5
Report
Fold Replies
- Bluem:
  can
  2021-05-25
  Reply
  Report
- Dree91:
  Pls reply to this comment in return ?
  2021-05-25
  Reply
  Report
- Qarah:
  Thanks
  2021-06-04
  Reply
  Report
Tazjonz
·2021-05-25
Johnson baby
Reply
3
Report
Fold Replies
- Ajinomoto:
  Defensive stock + Investment .
  2021-05-25
  Reply
  Report
- Bluem:
  mM
  2021-05-25
  Reply
  Report
- Tazjonz:
  Comment ans mM
  2021-05-25
  Reply
  Report
Shadotaiger
·2021-05-25
buy!
Reply
2
Report
sh99
·2021-05-25
comment pls
Reply
3
Report
Fold Replies
- Shadotaiger:
  pls reply thanks!
  2021-05-25
  Reply
  Report
- Huatmoney:
  Ok
  2021-05-25
  Reply
  Report
equanimity
·2021-05-25
Buy pfize instead
Reply
2
Report
Fold Replies
- Shadotaiger:
  pls reply thanks!
  2021-05-25
  Reply
  Report
TheOneeee
·2021-05-25
Any thought on this
Reply
2
Report
TheOneeee
·2021-05-25
Any thoughts on this? Haven bought any of this
Reply
2
Report
Calvingoh93
·2021-05-25
Buy
Reply
5
Report
Fold Replies
- Calvingoh93Replying toflyingsimon:
  U eee what.
  2021-05-26
  Reply
  Report
- flyingsimonReplying toCalvingoh93:
  Eeeeee
  2021-05-26
  Reply
  Report
- Calvingoh93:
  ??
  2021-05-25
  Reply
  Report
View more 2 comments
LWayne
·2021-05-25
Is this a paid post ?
Reply
2
Report
Fold Replies
- Shadotaiger:
  pls reply thanks!
  2021-05-25
  Reply
  Report
Jassss
·2021-05-25
Like and comment pls
Reply
7
Report
Fold Replies
- Jassss:
  Yeah
  2021-05-25
  Reply
  Report
- KLS:
  Buy
  2021-05-25
  Reply
  Report
- Calvingoh93:
  Buy
  2021-05-25
  Reply
  Report
View more 1 comments
Cfgramos
·2021-05-25
Unfortunately J&J ranks still ranks 3rd among the vaccine.
Reply
4
Report
Fold Replies
- Jassss:
  Yeah
  2021-05-25
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2138716979?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-05-25 17:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2138716979","market":"us","top_or_hot":-1,"title":"Is Johnson & Johnson a Buy for Summer 2021?","media":"Motley Fool","content":"<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","article_id":"2138716979","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","pubTimestamp":1621935000,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生"},"translate_title":"强生是2021年夏季的买主吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9},"content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":138299439,"gmtCreate":1621940620721,"gmtModify":1704364794474,"author":{"id":"3577082443804507","authorId":"3577082443804507","name":"Ajinomoto","avatar":"https://static.tigerbbs.com/2cf9b6c2dc1db3b2efff9a5448092468","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577082443804507","authorIdStr":"3577082443804507"},"htmlText":"Denfensive stock .&nbsp;","listText":"Denfensive stock .&nbsp;","text":"Denfensive stock .","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/138299439","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4443842,"gmtCreate":1621941399635,"gmtModify":1680790868499,"authorId":3575688888451618,"author":{"id":3575688888451618,"idStr":"3575688888451618","authorId":3575688888451618,"name":"Niki2307","avatar":"https://static.tigerbbs.com/76a9bfe7f6ca2e96a15f98f0d050e22c","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.04","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":3,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138299439,"type":1,"supId":0,"prevId":0,"content":"???","text":"???","html":"???"}],"langContent":"EN"},{"id":138290041,"gmtCreate":1621940520983,"gmtModify":1704364791696,"author":{"id":"3585033050463499","authorId":"3585033050463499","name":"JamieB","avatar":"https://static.tigerbbs.com/dbff582b7a275a2c0262986b48d5cc0a","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3585033050463499","authorIdStr":"3585033050463499"},"htmlText":"Not bad","listText":"Not bad","text":"Not bad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/138290041","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":138206012,"gmtCreate":1621940038336,"gmtModify":1704364783676,"author":{"id":"3573650696942499","authorId":"3573650696942499","name":"AlvintheTige","avatar":"https://static.tigerbbs.com/460880ecc1fc5fce82d547ef0fbb02da","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":4,"crmLevelSwitch":1,"idStr":"3573650696942499","authorIdStr":"3573650696942499"},"htmlText":"Not sure but u need to see the company fundamentals!!&nbsp;","listText":"Not sure but u need to see the company fundamentals!!&nbsp;","text":"Not sure but u need to see the company fundamentals!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/138206012","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4443729,"gmtCreate":1621940438561,"gmtModify":1680790867254,"authorId":3573464435831021,"author":{"id":3573464435831021,"idStr":"3573464435831021","authorId":3573464435831021,"name":"halforc","avatar":"https://community-static.tradeup.com/news/b984316e42fcf478d58db749e45ab05b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138206012,"type":1,"supId":0,"prevId":0,"content":"<u>agree</u>","text":"<u>agree</u>","html":"<u>agree</u>"},{"id":4443749,"gmtCreate":1621940541250,"gmtModify":1680790862020,"authorId":3572018203797244,"author":{"id":3572018203797244,"idStr":"3572018203797244","authorId":3572018203797244,"name":"theunmouse","avatar":"https://static.tigerbbs.com/c336181da66212b3d13c0ea59b6f69b5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138206012,"type":1,"supId":0,"prevId":0,"content":"True","text":"True","html":"True"}],"langContent":"EN"},{"id":138208870,"gmtCreate":1621939941090,"gmtModify":1704364783015,"author":{"id":"3564927108798920","authorId":"3564927108798920","name":"Uday","avatar":"https://static.tigerbbs.com/ba94e30caea713924bb15494e571fb48","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3564927108798920","authorIdStr":"3564927108798920"},"htmlText":"Good stock","listText":"Good stock","text":"Good stock","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/138208870","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4457570,"gmtCreate":1622032999057,"gmtModify":1680791104272,"authorId":3563863691814974,"author":{"id":3563863691814974,"idStr":"3563863691814974","authorId":3563863691814974,"name":"Al385","avatar":"https://static.tigerbbs.com/51b962289811e9774fd45f1320a21259","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138208870,"type":1,"supId":0,"prevId":0,"content":"True","text":"True","html":"True"},{"id":4443738,"gmtCreate":1621940508900,"gmtModify":1680790862525,"authorId":3574836626532677,"author":{"id":3574836626532677,"idStr":"3574836626532677","authorId":3574836626532677,"name":"Raae","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138208870,"type":1,"supId":0,"prevId":0,"content":"??","text":"??","html":"??"}],"langContent":"EN"},{"id":138201389,"gmtCreate":1621939808941,"gmtModify":1704364781190,"author":{"id":"3582060513966213","authorId":"3582060513966213","name":"Shadowrider","avatar":"https://static.tigerbbs.com/5a097dc665f46a3e5b535d2fd63e682b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582060513966213","authorIdStr":"3582060513966213"},"htmlText":"Buy?","listText":"Buy?","text":"Buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/138201389","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":138209855,"gmtCreate":1621939630477,"gmtModify":1704364778371,"author":{"id":"3580746005297647","authorId":"3580746005297647","name":"Tatsuya","avatar":"https://static.tigerbbs.com/9e704bb3e3180783f322dc964a67d550","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"idStr":"3580746005297647","authorIdStr":"3580746005297647"},"htmlText":"J&amp;J vaccine","listText":"J&amp;J vaccine","text":"J&J vaccine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/138209855","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4443740,"gmtCreate":1621940514779,"gmtModify":1680790861928,"authorId":3574836626532677,"author":{"id":3574836626532677,"idStr":"3574836626532677","authorId":3574836626532677,"name":"Raae","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138209855,"type":1,"supId":0,"prevId":0,"content":"??","text":"??","html":"??"}],"langContent":"EN"},{"id":138200497,"gmtCreate":1621939585719,"gmtModify":1704364777376,"author":{"id":"3573771226233818","authorId":"3573771226233818","name":"iImba","avatar":"https://static.tigerbbs.com/2253c7a4701d3d505950766c3e8c4837","vip":1,"crmLevel":8,"crmLevelSwitch":1,"idStr":"3573771226233818","authorIdStr":"3573771226233818"},"htmlText":"No thanks","listText":"No thanks","text":"No thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/138200497","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4443667,"gmtCreate":1621939818112,"gmtModify":1680790863016,"authorId":3582060513966213,"author":{"id":3582060513966213,"idStr":"3582060513966213","authorId":3582060513966213,"name":"Shadowrider","avatar":"https://static.tigerbbs.com/5a097dc665f46a3e5b535d2fd63e682b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138200497,"type":1,"supId":0,"prevId":0,"content":"Good","text":"Good","html":"Good"}],"langContent":"EN"},{"id":138673063,"gmtCreate":1621938456452,"gmtModify":1704364764531,"author":{"id":"3574409680880402","authorId":"3574409680880402","name":"Egging","avatar":"https://static.tigerbbs.com/5d5b3caed5b1dc46f9f3a4e05eef58cb","vip":1,"crmLevel":3,"crmLevelSwitch":1,"idStr":"3574409680880402","authorIdStr":"3574409680880402"},"htmlText":"LIKE N COMMENT&nbsp;","listText":"LIKE N COMMENT&nbsp;","text":"LIKE N COMMENT","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/138673063","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4444169,"gmtCreate":1621944241211,"gmtModify":1680790869475,"authorId":3582681835792049,"author":{"id":3582681835792049,"idStr":"3582681835792049","authorId":3582681835792049,"name":"Pplymm","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138673063,"type":1,"supId":0,"prevId":0,"content":"Comment for comment pls!","text":"Comment for comment pls!","html":"Comment for comment pls!"},{"id":4443647,"gmtCreate":1621939613412,"gmtModify":1680790868294,"authorId":3580746005297647,"author":{"id":3580746005297647,"idStr":"3580746005297647","authorId":3580746005297647,"name":"Tatsuya","avatar":"https://static.tigerbbs.com/9e704bb3e3180783f322dc964a67d550","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":"60.99%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138673063,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":4443680,"gmtCreate":1621939931024,"gmtModify":1680790867626,"authorId":3580746005297647,"author":{"id":3580746005297647,"idStr":"3580746005297647","authorId":3580746005297647,"name":"Tatsuya","avatar":"https://static.tigerbbs.com/9e704bb3e3180783f322dc964a67d550","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":"60.99%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3581036261146444,"repliedAuthor":{"id":3581036261146444,"idStr":"3581036261146444","authorId":3581036261146444,"name":"Dsd","avatar":"https://static.tigerbbs.com/2a1957746498df0232ae53ac81018443","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":138673063,"type":1,"supId":4443647,"prevId":4443659,"content":"...","text":"...","html":"..."},{"id":4443659,"gmtCreate":1621939713761,"gmtModify":1680790865560,"authorId":3581036261146444,"author":{"id":3581036261146444,"idStr":"3581036261146444","authorId":3581036261146444,"name":"Dsd","avatar":"https://static.tigerbbs.com/2a1957746498df0232ae53ac81018443","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138673063,"type":1,"supId":4443647,"prevId":0,"content":"...","text":"...","html":"..."},{"id":4443630,"gmtCreate":1621939485409,"gmtModify":1680790859494,"authorId":3578653033561627,"author":{"id":3578653033561627,"idStr":"3578653033561627","authorId":3578653033561627,"name":"Jefflim","avatar":"https://community-static.tradeup.com/news/59e2bd04cc5de36cce93c966dde9390b","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.26","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138673063,"type":1,"supId":0,"prevId":0,"content":"Pls return <u>thks</u>","text":"Pls return <u>thks</u>","html":"Pls return <u>thks</u>"}],"langContent":"EN"},{"id":138670267,"gmtCreate":1621938334159,"gmtModify":1704364762566,"author":{"id":"3573703375513385","authorId":"3573703375513385","name":"JonLucky","avatar":"https://static.tigerbbs.com/15afb66e92e4e4d6d1a8e9b7854e9d5e","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1,"idStr":"3573703375513385","authorIdStr":"3573703375513385"},"htmlText":"Perceptions always loom larger than reality.","listText":"Perceptions always loom larger than reality.","text":"Perceptions always loom larger than reality.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/138670267","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4443535,"gmtCreate":1621938364913,"gmtModify":1680790859193,"authorId":3574639507377836,"author":{"id":3574639507377836,"idStr":"3574639507377836","authorId":3574639507377836,"name":"Kikiooi","avatar":"https://static.tigerbbs.com/81135f833a61d8d0899dff1c77b07e72","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138670267,"type":1,"supId":0,"prevId":0,"content":"AGree. ","text":"AGree. ","html":"AGree. "}],"langContent":"EN"},{"id":138647718,"gmtCreate":1621938287334,"gmtModify":1704364761906,"author":{"id":"3570439473038184","authorId":"3570439473038184","name":"Qarah","avatar":"https://static.tigerbbs.com/48285a44928a897dd5f255c626d5e9e1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570439473038184","authorIdStr":"3570439473038184"},"htmlText":"Like and comment pls&nbsp;","listText":"Like and comment pls&nbsp;","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/138647718","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4443742,"gmtCreate":1621940526339,"gmtModify":1680790862458,"authorId":3575980094521663,"author":{"id":3575980094521663,"idStr":"3575980094521663","authorId":3575980094521663,"name":"Bluem","avatar":"https://static.tigerbbs.com/2ea0046117889d9c87b13a313a480e69","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138647718,"type":1,"supId":4443689,"prevId":0,"content":"<u>can</u>","text":"<u>can</u>","html":"<u>can</u>"},{"id":4443689,"gmtCreate":1621940000224,"gmtModify":1680790861249,"authorId":3579640404391166,"author":{"id":3579640404391166,"idStr":"3579640404391166","authorId":3579640404391166,"name":"Dree91","avatar":"https://static.tigerbbs.com/e08fc9c98b4a247f7123a7b3a3c93d35","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138647718,"type":1,"supId":0,"prevId":0,"content":"Pls reply to this comment in return ?","text":"Pls reply to this comment in return ?","html":"Pls reply to this comment in return ?"},{"id":4580164,"gmtCreate":1622813099168,"gmtModify":1663227958045,"authorId":3570439473038184,"author":{"id":3570439473038184,"idStr":"3570439473038184","authorId":3570439473038184,"name":"Qarah","avatar":"https://static.tigerbbs.com/48285a44928a897dd5f255c626d5e9e1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138647718,"type":1,"supId":4443689,"prevId":0,"content":"Thanks","text":"Thanks","html":"Thanks"}],"langContent":"EN"},{"id":138647955,"gmtCreate":1621938243677,"gmtModify":1704364760753,"author":{"id":"3578567927092479","authorId":"3578567927092479","name":"Tazjonz","avatar":"https://static.tigerbbs.com/f84e5692e6809277d605d8442cdc7efa","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578567927092479","authorIdStr":"3578567927092479"},"htmlText":"Johnson baby&nbsp;","listText":"Johnson baby&nbsp;","text":"Johnson baby","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/138647955","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4444101,"gmtCreate":1621943612029,"gmtModify":1680790874742,"authorId":3577082443804507,"author":{"id":3577082443804507,"idStr":"3577082443804507","authorId":3577082443804507,"name":"Ajinomoto","avatar":"https://static.tigerbbs.com/2cf9b6c2dc1db3b2efff9a5448092468","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138647955,"type":1,"supId":0,"prevId":0,"content":"Defensive stock + Investment . ","text":"Defensive stock + Investment . ","html":"Defensive stock + Investment . "},{"id":4443746,"gmtCreate":1621940533722,"gmtModify":1680790864252,"authorId":3575980094521663,"author":{"id":3575980094521663,"idStr":"3575980094521663","authorId":3575980094521663,"name":"Bluem","avatar":"https://static.tigerbbs.com/2ea0046117889d9c87b13a313a480e69","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138647955,"type":1,"supId":4443520,"prevId":0,"content":"<u>mM</u>","text":"<u>mM</u>","html":"<u>mM</u>"},{"id":4443520,"gmtCreate":1621938257700,"gmtModify":1680790859310,"authorId":3578567927092479,"author":{"id":3578567927092479,"idStr":"3578567927092479","authorId":3578567927092479,"name":"Tazjonz","avatar":"https://static.tigerbbs.com/f84e5692e6809277d605d8442cdc7efa","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.07","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138647955,"type":1,"supId":0,"prevId":0,"content":"Comment ans mM","text":"Comment ans mM","html":"Comment ans mM"}],"langContent":"EN"},{"id":138644321,"gmtCreate":1621938187863,"gmtModify":1704364759607,"author":{"id":"3575958434174944","authorId":"3575958434174944","name":"Shadotaiger","avatar":"https://static.tigerbbs.com/c26a9d060fabab1c1347edbfc7329574","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575958434174944","authorIdStr":"3575958434174944"},"htmlText":"buy!","listText":"buy!","text":"buy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/138644321","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":138640492,"gmtCreate":1621937590016,"gmtModify":1704364749895,"author":{"id":"3582013951378523","authorId":"3582013951378523","name":"sh99","avatar":"https://static.tigerbbs.com/95985dfcd15851145b63b9903fdb5bfc","vip":1,"hat":"https://static.tigerbbs.com/6444b4970948c1077534c593eccd6d16","crmLevel":4,"crmLevelSwitch":0,"idStr":"3582013951378523","authorIdStr":"3582013951378523"},"htmlText":"&nbsp;comment pls","listText":"&nbsp;comment pls","text":"comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/138640492","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4443497,"gmtCreate":1621938149810,"gmtModify":1680790864473,"authorId":3575958434174944,"author":{"id":3575958434174944,"idStr":"3575958434174944","authorId":3575958434174944,"name":"Shadotaiger","avatar":"https://static.tigerbbs.com/c26a9d060fabab1c1347edbfc7329574","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138640492,"type":1,"supId":4443387,"prevId":0,"content":"pls reply thanks!","text":"pls reply thanks!","html":"pls reply thanks!"},{"id":4443387,"gmtCreate":1621937643302,"gmtModify":1680790851431,"authorId":3579523962373263,"author":{"id":3579523962373263,"idStr":"3579523962373263","authorId":3579523962373263,"name":"Huatmoney","avatar":"https://static.tigerbbs.com/b4513f3d6c5b842d70f3a1a7af1a1afa","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138640492,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":138654524,"gmtCreate":1621937479868,"gmtModify":1704364746505,"author":{"id":"3561196982108176","authorId":"3561196982108176","name":"equanimity","avatar":"https://static.tigerbbs.com/576e6745dd13ebdc7f35c86ea3532b7e","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3561196982108176","authorIdStr":"3561196982108176"},"htmlText":"Buy pfize instead&nbsp;","listText":"Buy pfize instead&nbsp;","text":"Buy pfize instead","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/138654524","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4443499,"gmtCreate":1621938155702,"gmtModify":1680790863256,"authorId":3575958434174944,"author":{"id":3575958434174944,"idStr":"3575958434174944","authorId":3575958434174944,"name":"Shadotaiger","avatar":"https://static.tigerbbs.com/c26a9d060fabab1c1347edbfc7329574","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138654524,"type":1,"supId":0,"prevId":0,"content":"pls reply thanks!","text":"pls reply thanks!","html":"pls reply thanks!"}],"langContent":"EN"},{"id":138655143,"gmtCreate":1621937402382,"gmtModify":1704364744726,"author":{"id":"3573731031209763","authorId":"3573731031209763","name":"TheOneeee","avatar":"https://static.tigerbbs.com/9d5758738e99f8c2924ceb750474d825","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3573731031209763","authorIdStr":"3573731031209763"},"htmlText":"Any thought on this","listText":"Any thought on this","text":"Any thought on this","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/138655143","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":138655387,"gmtCreate":1621937389749,"gmtModify":1704364744404,"author":{"id":"3573731031209763","authorId":"3573731031209763","name":"TheOneeee","avatar":"https://static.tigerbbs.com/9d5758738e99f8c2924ceb750474d825","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3573731031209763","authorIdStr":"3573731031209763"},"htmlText":"Any thoughts on this? Haven bought any of this","listText":"Any thoughts on this? Haven bought any of this","text":"Any thoughts on this? Haven bought any of this","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/138655387","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":138652678,"gmtCreate":1621937361894,"gmtModify":1704364743431,"author":{"id":"3583902158543371","authorId":"3583902158543371","name":"Calvingoh93","avatar":"https://static.tigerbbs.com/f39861e6ea06d8827da08f30bde8394c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3583902158543371","authorIdStr":"3583902158543371"},"htmlText":"Buy&nbsp;","listText":"Buy&nbsp;","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/138652678","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4448237,"gmtCreate":1621984537323,"gmtModify":1680790946098,"authorId":3583902158543371,"author":{"id":3583902158543371,"idStr":"3583902158543371","authorId":3583902158543371,"name":"Calvingoh93","avatar":"https://static.tigerbbs.com/f39861e6ea06d8827da08f30bde8394c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3582676161346158,"repliedAuthor":{"id":3582676161346158,"idStr":"3582676161346158","authorId":3582676161346158,"name":"flyingsimon","avatar":"https://static.tigerbbs.com/c7ff5f4cfd6f62deb6f4d3345b5207b3","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.24","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":138652678,"type":1,"supId":4443501,"prevId":4447358,"content":"U eee what. ","text":"U eee what. ","html":"U eee what. "},{"id":4447358,"gmtCreate":1621969422168,"gmtModify":1680790925747,"authorId":3582676161346158,"author":{"id":3582676161346158,"idStr":"3582676161346158","authorId":3582676161346158,"name":"flyingsimon","avatar":"https://static.tigerbbs.com/c7ff5f4cfd6f62deb6f4d3345b5207b3","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.24","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3583902158543371,"repliedAuthor":{"id":3583902158543371,"idStr":"3583902158543371","authorId":3583902158543371,"name":"Calvingoh93","avatar":"https://static.tigerbbs.com/f39861e6ea06d8827da08f30bde8394c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":138652678,"type":1,"supId":4443501,"prevId":4444016,"content":"Eeeeee","text":"Eeeeee","html":"Eeeeee"},{"id":4444016,"gmtCreate":1621942929458,"gmtModify":1680790877610,"authorId":3583902158543371,"author":{"id":3583902158543371,"idStr":"3583902158543371","authorId":3583902158543371,"name":"Calvingoh93","avatar":"https://static.tigerbbs.com/f39861e6ea06d8827da08f30bde8394c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138652678,"type":1,"supId":4443501,"prevId":0,"content":"??","text":"??","html":"??"},{"id":4443501,"gmtCreate":1621938163775,"gmtModify":1680790860285,"authorId":3575958434174944,"author":{"id":3575958434174944,"idStr":"3575958434174944","authorId":3575958434174944,"name":"Shadotaiger","avatar":"https://static.tigerbbs.com/c26a9d060fabab1c1347edbfc7329574","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138652678,"type":1,"supId":0,"prevId":0,"content":"pls reply thanks!","text":"pls reply thanks!","html":"pls reply thanks!"},{"id":4453395,"gmtCreate":1622004463270,"gmtModify":1663227354636,"authorId":3582676161346158,"author":{"id":3582676161346158,"idStr":"3582676161346158","authorId":3582676161346158,"name":"flyingsimon","avatar":"https://static.tigerbbs.com/c7ff5f4cfd6f62deb6f4d3345b5207b3","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.24","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3583902158543371,"repliedAuthor":{"id":3583902158543371,"idStr":"3583902158543371","authorId":3583902158543371,"name":"Calvingoh93","avatar":"https://static.tigerbbs.com/f39861e6ea06d8827da08f30bde8394c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":138652678,"type":1,"supId":4443501,"prevId":4448237,"content":"Hmmmm","text":"Hmmmm","html":"Hmmmm"}],"langContent":"EN"},{"id":138656461,"gmtCreate":1621937271253,"gmtModify":1704364742302,"author":{"id":"3564307384077743","authorId":"3564307384077743","name":"LWayne","avatar":"https://static.itradeup.com/news/95dd7493a26e1c3e9a33a2d16eaa037b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3564307384077743","authorIdStr":"3564307384077743"},"htmlText":"Is this a paid post ?","listText":"Is this a paid post ?","text":"Is this a paid post ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/138656461","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4443505,"gmtCreate":1621938170699,"gmtModify":1680790860349,"authorId":3575958434174944,"author":{"id":3575958434174944,"idStr":"3575958434174944","authorId":3575958434174944,"name":"Shadotaiger","avatar":"https://static.tigerbbs.com/c26a9d060fabab1c1347edbfc7329574","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138656461,"type":1,"supId":0,"prevId":0,"content":"pls reply thanks!","text":"pls reply thanks!","html":"pls reply thanks!"}],"langContent":"EN"},{"id":138651951,"gmtCreate":1621937089473,"gmtModify":1704364738907,"author":{"id":"3574244375315958","authorId":"3574244375315958","name":"Jassss","avatar":"https://static.tigerbbs.com/a1a74261bc0d795b37c8c963ee5393f0","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"idStr":"3574244375315958","authorIdStr":"3574244375315958"},"htmlText":"Like and comment pls&nbsp;","listText":"Like and comment pls&nbsp;","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/138651951","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4444659,"gmtCreate":1621947167723,"gmtModify":1680790881509,"authorId":3574244375315958,"author":{"id":3574244375315958,"idStr":"3574244375315958","authorId":3574244375315958,"name":"Jassss","avatar":"https://static.tigerbbs.com/a1a74261bc0d795b37c8c963ee5393f0","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.18","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138651951,"type":1,"supId":4443343,"prevId":0,"content":"Yeah","text":"Yeah","html":"Yeah"},{"id":4443314,"gmtCreate":1621937144808,"gmtModify":1680790858823,"authorId":3551655093075927,"author":{"id":3551655093075927,"idStr":"3551655093075927","authorId":3551655093075927,"name":"KLS","avatar":"https://static.tigerbbs.com/60fe00969bbce4cfecf0d17a38c77628","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138651951,"type":1,"supId":0,"prevId":0,"content":"Buy","text":"Buy","html":"Buy"},{"id":4443343,"gmtCreate":1621937374638,"gmtModify":1680790852660,"authorId":3583902158543371,"author":{"id":3583902158543371,"idStr":"3583902158543371","authorId":3583902158543371,"name":"Calvingoh93","avatar":"https://static.tigerbbs.com/f39861e6ea06d8827da08f30bde8394c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138651951,"type":1,"supId":0,"prevId":0,"content":"Buy","text":"Buy","html":"Buy"},{"id":4443325,"gmtCreate":1621937229499,"gmtModify":1680790852230,"authorId":3574244375315958,"author":{"id":3574244375315958,"idStr":"3574244375315958","authorId":3574244375315958,"name":"Jassss","avatar":"https://static.tigerbbs.com/a1a74261bc0d795b37c8c963ee5393f0","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.18","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138651951,"type":1,"supId":4443314,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":138627918,"gmtCreate":1621936699434,"gmtModify":1704364733175,"author":{"id":"3577318628836449","authorId":"3577318628836449","name":"Cfgramos","avatar":"https://static.tigerbbs.com/8e4f5dee285970cb0d50c61a4302a33f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577318628836449","authorIdStr":"3577318628836449"},"htmlText":"Unfortunately J&amp;J ranks still ranks&nbsp;3rd among the vaccine.","listText":"Unfortunately J&amp;J ranks still ranks&nbsp;3rd among the vaccine.","text":"Unfortunately J&J ranks still ranks 3rd among the vaccine.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/138627918","repostId":2138716979,"repostType":4,"repost":{"id":"2138716979","pubTimestamp":1621935000,"share":"https://ttm.financial/m/news/2138716979?lang=&edition=fundamental","pubTime":"2021-05-25 17:30","market":"us","language":"en","title":"Is Johnson & Johnson a Buy for Summer 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138716979","media":"Motley Fool","summary":"This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?","content":"<p>Despite the economic turmoil of the past year, the <b>S&amp;P 500 </b>has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical <b>Johnson &amp; Johnson&nbsp;</b>(NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.&nbsp;</p><p>That was a major disappointment for shareholders, many of whom were betting that a successful J&amp;J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?&nbsp;</p><h2>What happened?&nbsp;</h2><p>Last year, Johnson &amp; Johnson (with $1 billion in federal support) developed a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.</p><p>However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson &amp; Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.</p><p>Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the <b>Pfizer </b>and&nbsp;<b>Moderna</b> vaccines.&nbsp;</p><p>Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, <b>Emergent Biosciences </b>(NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson &amp; Johnson's vaccine with ingredients meant for <b>AstraZeneca</b>'s coronavirus vaccine.&nbsp;</p><p>AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson &amp; Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.</p><h2>Looking past the vaccine drama&nbsp;</h2><p>Investing in Johnson &amp; Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.</p><p>Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson &amp; Johnson is already a mega-corporation.</p><p>There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic.&nbsp;</p><p>A key driver behind Johnson &amp; Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson &amp; Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.</p><h2>What's the verdict?&nbsp;</h2><p>Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson &amp; Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&amp;P 500.</p><p>Overall, given the strength of its core operations, its great R&amp;D pipeline, and its cheap valuation, Johnson &amp; Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson a Buy for Summer 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson a Buy for Summer 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/05/25/is-johnson-johnson-a-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138716979","content_text":"Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE:JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? What happened? Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines. Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (NYSE:EBS), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.Looking past the vaccine drama Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic. A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.What's the verdict? Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4443311,"gmtCreate":1621937127567,"gmtModify":1680790854221,"authorId":3574244375315958,"author":{"id":3574244375315958,"idStr":"3574244375315958","authorId":3574244375315958,"name":"Jassss","avatar":"https://static.tigerbbs.com/a1a74261bc0d795b37c8c963ee5393f0","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.18","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":138627918,"type":1,"supId":0,"prevId":0,"content":"Yeah","text":"Yeah","html":"Yeah"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":49,"commentSize":24,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}